Abstract #973797: 6-Month Subcutaneous Leuprolide Acetate Effectively Suppressed Rate of Bone Maturation and Increased Predicted Adult Height Without Significant Increase in BMI in Children with Central Precocious Puberty

The first small-volume, long-acting, subcutaneously administered GnRHa treatment for central precocious puberty (CPP) was approved for use in 2020. Subcutaneous leuprolide acetate (45 mg) administered at a 6-month interval effectively suppressed pubertal hormones and stopped or caused regression of pubertal progression. Eighty-seven percent of children achieved LH< 4 IU/L at Wk24 in a Phase III trial evaluating the efficacy and safety, and 7/8 children who did not achieve the primary efficacy endpoint achieved LH< 5 IU/L by Wk48 and showed signs of effective clinical suppression. We present secondary analyses of bone age (BA) advancement, weight, BMI, growth rate, and predicted adult height (PAH).